The U.S. Food and Drug Administration approved dupilumab for eosinophilic esophagitis in patients 12 and up in May 2022. This… Read more »
The U.S. Food and Drug Administration approved dupilumab for eosinophilic esophagitis in patients 12 and up in May 2022. This… Read more »